A brain health expert looks ahead to phase 3 testing
When interim results from the PRIME study of aducanumab for Alzheimer’s disease were recently published in Nature, buzz about the study in the consumer media was instant — and sometimes hyperbolic.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Despite the encouraging findings that this monoclonal antibody reduced amyloid-beta plaques in a dose-dependent fashion, it’s important to remind excited patients and families of the study’s relatively preliminary nature. Despite its inclusion of 165 patients and its randomized, placebo-controlled design, the PRIME study was still a phase 1b trial.
Confirmation of its findings is being sought in ongoing phase 3 trials, and Cleveland Clinic Lou Ruvo Center for Brain Health is a participating center. In this video, one of the Cleveland Clinic neurologists involved in phase 3 testing of aducanumab — James Leverenz, MD — shares perspectives on the PRIME findings, what they mean for the amyloid hypothesis, and the road ahead for aducanumab.
Pilot study confirms feasibility of conducting additional research on the novel treatment
Longer hospitalization does not mean a safer, faster recovery for patients age 70+
Structured data helps identify older adults at risk for poor outcomes, defines patients who require more comprehensive assessments
Self-administered tool can be completed in 10 minutes in waiting room
Social prescribing turns leisure activities into good “medicine”
A large geriatric study aims to find the answers
Analysis underscores how telehealth can help pinpoint elder abuse